2015 GI Cancers Symposium - Saturday
Read More
Chiara Cremolini, MD, U.O. Oncologia Medica II, Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori presenting the poster for abstract #657, "FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group."
San Francisco, CA - 2015 Gastrointestinal Cancers Symposium : Chiara Cremolini, MD, U.O. Oncologia Medica II, Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori presenting the poster for abstract #657, "FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group." during General Poster Session C at the Gastrointestinal Cancers Symposium 2015 here today, Saturday January 17, 2015. The Symposium is supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology and the AGA Institute. Over 3,000 physicians, researchers and allied healthcare professionals are attending the meeting which is being held at the Moscone West center in San Francisco and features the latest Gastrointestinal Cancers research in the areas of basic and clinical science. Date: Saturday January 17, 2015. Photo by © ASCO/Todd Buchanan 2015 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154. GI15_Communications
